dr. bellmunt shares keynote-045 data for pembrolizumab versus chemotherapy in bladder cancer
Published 7 years ago • 635 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
2:58
dr. bellmunt discusses follow-up data for pembrolizumab vs chemotherapy in bladder cancer
-
0:51
impact of the keynote-045 study comparing pembrolizumab and chemotherapy in bladder cancer
-
1:09
keynote-045 – pembrolizumab as second-line treatment in urothelial carcinoma
-
1:18
dr. plimack on keynote-045 trial for pembrolizumab in urothelial carcinoma
-
1:30
dr. bellmunt on pd-l1 data in bladder cancer
-
2:06
dr. bellmunt highlights immunotherapy options in bladder cancer
-
0:57
dr. petrylak on the keynote-045 trial for urothelial carcinoma
-
1:13
dr. bellmunt on challenges with immunotherapy in bladder cancer
-
0:58
significance of keynote-045 trial of pembrolizumab vs chemotherapy in urothelial carcinoma
-
1:54
two-year follow-up results from keynote-045 study in urothelial carcinoma
-
1:09
dr. plimack on frontline pembrolizumab for urothelial carcinoma
-
4:49
hrqol of pembrolizumab vs. chemotherapy for previously treated...
-
2:22
keynote-057: extended follow-up of pembrolizumab in bladder cancer
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
2:57
highlights in bladder canceres: keynote-045 keynote-052 dr. fabio schutz
-
1:18
dr. plimack on combo of pembrolizumab/epacodostat in bladder cancer
-
0:51
dr. balar on the approval of pembrolizumab for bladder cancer
-
4:00
overview of urothelial carcinoma treatment landscape – the promise of immunotherapy
-
1:05
dr. petrylak on combinations with pembrolizumab in urothelial carcinoma